AbCellera Biologics Inc
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: −8.52%.
Did ABCL Beat Earnings? Q4 2025 Results
AbCellera Biologics delivered a sharp earnings beat in Q4 2025, with revenue of $44.90 million coming in well above the $6.71 million consensus estimate, a 569.55% positive surprise, as the quarter's results were driven primarily by an upfront payment from a patent litigation settlement. That single item propelled quarterly revenue 789.1% higher year over year and lifted full-year 2025 revenue to $75.13 million, compared to $28.83 million in 2024. On the bottom line, AbCellera posted a loss of $0.03 per share, beating the $0.18 consensus estimate by 83.33%, as the settlement proceeds sharply narrowed the quarterly net loss to $8.90 million. The strong print coincided with the company's transition to a clinical-stage biotech, having advanced ABCL635 into Phase 2 and ABCL575 into Phase 1 trials during the year; both programs are expected to deliver topline readouts in the second half of 2026. With roughly $700 million in total available liquidity, including non-dilutive government funding, AbCellera says it is funded well beyond three years, supporting continued pipeline investment and at least three anticipated IND submissions in 2027. Shares rose nearly 19% following the results.
- Upfront settlement payment from patent litigation drove Q4 2025 revenue of $44.9 million, representing 60% of full-year revenue
- Licensing and royalty revenue surged to $46.9 million from $1.0 million in FY 2024
- Completion of multi-year platform investments reduced capital expenditure requirements
“In 2025, AbCellera successfully delivered on all its corporate priorities, transitioned to a clinical-stage biotech company, and ended the year with approximately $700 million in available liquidity to execute on our strategy.”
AbCellera Biologics CEO, on the earnings call
Forward Guidance & Outlook
AbCellera's 2026 priorities include advancing ABCL635 and ABCL575 to topline Phase 1 clinical trial readouts in H2 2026, progressing ABCL688 and ABCL386 through IND-enabling studies, and nominating at least one additional development candidate for IND-enabling activities. The company anticipates multiple catalysts in 2027 including late-stage development of ABCL635 in menopausal VMS, initiation of Phase 2 studies of ABCL635 in oncology VMS, options for further development or out-licensing of ABCL575, and IND submissions with initiation of Phase 1/2 studies for ABCL688, ABCL386, and a new development candidate. The internal pipeline is expected to produce 1-2 development candidates per year. Available liquidity of approximately $700 million is expected to fund operations well beyond three years.
ABCL YoY Financials
ABCL Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.